AbCellera Biologics (NASDAQ:ABCL) Research Coverage Started at Lake Street Capital

Lake Street Capital began coverage on shares of AbCellera Biologics (NASDAQ:ABCL – Free Report) in a report published on Wednesday, MarketBeat.com reports. The brokerage issued a buy rating and a $19.00 price target on the stock.

Several other equities research analysts have also issued reports on the stock. Stifel Nicolaus increased their target price on shares of AbCellera Biologics from $9.00 to $14.00 and gave the stock a “buy” rating in a research note on Tuesday, November 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AbCellera Biologics in a research note on Thursday, October 15th. Wall Street Zen upgraded AbCellera Biologics from a “sell” rating to a “hold” rating in a research report on Saturday, October 31st. Jefferies Financial Group restated a “buy” rating on shares of AbCellera Biologics in a research report on Monday. Finally, Truist Financial increased their target price on AbCellera Biologics from $12.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.75.

Read Our Latest Analysis on AbCellera Biologics

AbCellera Biologics Stock Down 7.7%

Shares of ABCL stock opened at $9.66 on Wednesday. AbCellera Biologics has a 52-week low of $2.74 and a 52-week high of $15.02. The stock has a market cap of $3.16 billion, a PE ratio of -20.14 and a beta of 1.59. The business has a 50-day simple moving average of $12.30 and a 200-day simple moving average of $7.41.

AbCellera Biologics (NASDAQ:ABCL – Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.04. AbCellera Biologics had a negative return on equity of 15.35% and a negative net margin of 218.54%. The company had revenue of $10.64 million during the quarter, compared to analysts’ expectations of $8.42 million. During the same period last year, the business earned ($0.19) earnings per share. Sell-side analysts anticipate that AbCellera Biologics will post -0.60 earnings per share for the current fiscal year.

Insider Buying and Selling

In other AbCellera Biologics news, major shareholder Holdings Ltd. Thermopylae acquired 60,565 shares of the business’s stock in a transaction on Thursday, November 12th. The stock was bought at an average price of $11.54 per share, for a total transaction of $698,920.10. Following the acquisition, the insider owned 56,194,662 shares in the company, valued at approximately $648,486,399.48. The trade was a 0.11% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 28.40% of the company’s stock.

Hedge Funds Weigh In On AbCellera Biologics

Institutional investors have recently added to or reduced their stakes in the stock. Robinhood Markets Inc. purchased a new position in AbCellera Biologics during the third quarter worth about $61,000. Blume Capital Management Inc. grew its position in AbCellera Biologics by 22.7% in the third quarter. Blume Capital Management Inc. now owns 5,501 shares of the company’s stock worth $80,000 after acquiring an additional 1,017 shares during the period. AssuredPartners Investment Advisors LLC purchased a new position in AbCellera Biologics in the second quarter worth approximately $80,000. Cetera Investment Advisers acquired a new stake in AbCellera Biologics during the third quarter worth $163,000. Finally, ProShare Advisors LLC lifted its stake in shares of AbCellera Biologics by 12.2% in the 3rd quarter. ProShare Advisors LLC now owns 11,235 shares of the company’s stock valued at $164,000 after purchasing an additional 1,224 shares during the last quarter. Hedge funds and other institutional investors own 61.42% of the company’s stock.

About AbCellera Biologics

(Get Free Report)

AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.

Recommended Stories

Analyst Recommendations for AbCellera Biologics (NASDAQ:ABCL)

Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.